HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma

• Published in: The American journal of surgical pathology Vol. 44; no. 8; pp. 1143 - 1148
• Main Authors: Naso, Julia R., Tsuji, Shoutaro, Churg, Andrew
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-08-2020; Copyright Wolters Kluwer Health, Inc. All rights reserved
• Subjects: Antibodies, Monoclonal - immunology; Antibody Specificity; Biomarkers, Tumor - immunology; Diagnosis, Differential; Epithelioid Cells - immunology; Epithelioid Cells - pathology; Female; Humans; Immunohistochemistry; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Male; Membrane Proteins - immunology; Mesothelioma - immunology; Mesothelioma - pathology; Mesothelioma, Malignant; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Tissue Array Analysis
• ISSN: 0147-5185; 1532-0979
• DOI: 10.1097/PAS.0000000000001469

Malignant mesothelioma can be difficult to distinguish from other malignancies, particularly non–small cell lung carcinomas (NSCLCs), without immunohistochemistry. However, conventional markers of mesothelial lineage all have variable degrees of cross-reactivity with other neoplasms, including NSCLCs, necessitating the use of multiple mesothelioma and carcinoma markers in every case for accurate diagnosis. A recently described monoclonal HEG homolog 1 (HEG1) antibody was proposed to be a specific marker for mesothelioma. Here we performed a large scale assessment of the SKM9-2 HEG1 antibody using tissue microarrays containing 69 epithelioid mesotheliomas, 32 sarcomatoid mesotheliomas, 167 NSCLCs, and 17 ovarian high-grade serous carcinomas. Strong membrane staining, usually diffuse, for HEG1 was seen in 65/69 (94%) epithelioid mesotheliomas, 0/60 pulmonary squamous cell carcinomas, 0/73 pulmonary adenocarcinomas, and 0/13 pulmonary large cell carcinomas. HEG1 showed staining in 14/32 (44%) sarcomatoid mesotheliomas compared with 0/21 sarcomatoid pulmonary carcinomas. Three of 17 (18%) high-grade serous carcinomas demonstrated membrane staining. Ten B3 thymoma whole sections were negative. On the microarrays, the conventional mesothelial markers calretinin, WT1, D2-40, and CK5/6 had sensitivities for epithelioid mesothelioma of 94%, 90%, 96%, and 91%, respectively. We conclude that HEG1 SKM9-2 antibody offers sensitivity comparable to conventional markers for epithelioid mesotheliomas, but provides considerably better specificity, such that the diagnosis of epithelioid mesothelioma versus NSCLC potentially could be confirmed with a combination of HEG1 and a suitable broad spectrum carcinoma marker such as claudin-4. HEG1 is specific but insensitive for separating sarcomatoid mesotheliomas from sarcomatoid lung carcinomas.